ALNYLAM PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 145.2 USD | -0.11% |
|
-4.56% | -24.16% |
| Apr. 08 | Sector Update: Health Care Stocks Flat to Higher Premarket Monday | MT |
| Apr. 08 | Sector Update: Health Care | MT |
Presenter SpeechPatrick Trucchio (Analysts)Hello, everyone, and thank you for joining the H.C....
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Alnylam Pharmaceuticals, Inc. is a clinical-stage company. The Company is engaged in developing mRNA cell therapies for the treatment of autoimmune diseases. The Companyâs lead product candidate, Descartes-08, is an autologous mRNA CAR-T directed against the B cell maturation antigen (BCMA). Descartes-08 targets BCMA, which exists on the surface of long-lived plasma cells and plasmacytoid dendritic cells. Descartes-08 is in Phase IIb clinical development for patients with generalized myasthenia gravis (MG). Its other product candidate includes Descartes-15 and Descartes-33. Descartes-15 is a next-generation, autologous anti-BCMA mRNA CAR-T. Using its proprietary technology and manufacturing platform, it designed Descartes-15 to be more resistant than Descartes-08 to recycling of the CAR upon multiple antigen exposures. It is developing Descartes-33 to deliver a combination of therapeutic proteins that target key drivers in the pathogenesis of autoimmunity.
Calendar
2024-05-02
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
145.2
USD
Average target price
220
USD
Spread / Average Target
+51.56%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -24.16% | 18.36B | |
| -1.82% | 41.35B | |
| +41.48% | 40.38B | |
| +2.56% | 39.05B | |
| -12.11% | 26.67B | |
| +3.09% | 24.07B | |
| +22.12% | 11.6B | |
| -3.74% | 11.68B | |
| +7.75% | 11.15B | |
| -19.38% | 9.78B |
- Stock Market
- Equities
- ALNY Stock
- News Alnylam Pharmaceuticals, Inc.
- Transcript : Alnylam Pharmaceuticals, Inc. Presents at H.C. Wainwright Global Investment Conference 2022, May-24-2022 07
